Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

1.

HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia.

Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):34-40.

PMID:
16123679
[PubMed - indexed for MEDLINE]
2.

Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.

Darwich L, Esteve A, Ruiz L, Paredes R, Bellido R, Cabrera C, Romeu J, Bofill M, Clotet B, Martinez-Picado J.

AIDS Res Hum Retroviruses. 2008 May;24(5):725-32. doi: 10.1089/aid.2007.0255.

PMID:
18462084
[PubMed - indexed for MEDLINE]
3.

Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.

Martín-Carbonero L, Gil P, García-Benayas T, Barreiro P, Blanco F, de Mendoza C, Maida I, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Dec;22(12):1231-5.

PMID:
17209764
[PubMed - indexed for MEDLINE]
4.

Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.

Cozzi-Lepri A, Phillips AN, Ruiz L, Clotet B, Loveday C, Kjaer J, Mens H, Clumeck N, Viksna L, Antunes F, Machala L, Lundgren JD; EuroSIDA Study Group.

AIDS. 2007 Mar 30;21(6):721-32.

PMID:
17413693
[PubMed - indexed for MEDLINE]
5.

Utility of interrupting antiretroviral treatment before HIV drug resistance testing in patients with persistently detectable low-level viremia.

Sirvent JL, Socas MM, Calzadilla CH, Lirola AM, Valls MR.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):111-3. No abstract available.

PMID:
16123693
[PubMed - indexed for MEDLINE]
6.

Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression.

Kristiansen TB, Pedersen AG, Eugen-Olsen J, Katzenstein TL, Lundgren JD.

Scand J Infect Dis. 2005;37(11-12):890-901.

PMID:
16308226
[PubMed - indexed for MEDLINE]
7.

Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults.

Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG.

J Virol. 2002 Nov;76(21):11104-12.

PMID:
12368352
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.

Stürmer M, Dauer B, Moesch M, Haberl A, Mueller A, Locher L, Knecht G, Hanke N, Doerr HW, Staszewski S.

Antivir Ther. 2007;12(1):25-30.

PMID:
17503744
[PubMed - indexed for MEDLINE]
9.

Lability of antiretroviral drug resistance mutations--correlates with immunological and virological responses.

Al Mazari A, Zomaya AY, Charleston M, Salem H, Maher A, Garsia RJ.

Curr HIV Res. 2007 Jul;5(4):430-9.

PMID:
17627506
[PubMed - indexed for MEDLINE]
10.

Effect of suppressing HIV viremia on the HIV progression of patients undergoing a genotype resistance test after treatment failure.

Zaccarelli M, Lorenzini P, Tozzi V, Forbici F, Ceccherini-Silberstein F, Gori C, D'Arrigo R, Trotta MP, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of the HIV Genotype Resistance Test (GRT) at the National Institute for Infectious Diseases "Lazzaro Spallanzani".

Infection. 2009 Jun;37(3):203-9. doi: 10.1007/s15010-008-8142-8. Epub 2009 Mar 9.

PMID:
19274429
[PubMed - indexed for MEDLINE]
11.

Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen.

Hatano H, Hunt P, Weidler J, Coakley E, Hoh R, Liegler T, Martin JN, Deeks SG.

Clin Infect Dis. 2006 Nov 15;43(10):1329-36. Epub 2006 Oct 6.

PMID:
17051502
[PubMed - indexed for MEDLINE]
Free Article
12.

Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.

Cohen C.

HIV Clin Trials. 2009 Mar-Apr;10(2):116-24. doi: 10.1310/hct1002-116. Review.

PMID:
19487182
[PubMed - indexed for MEDLINE]
13.

Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.

Badri SM, Adeyemi OM, Max BE, Hota BN, Barker DE.

AIDS Patient Care STDS. 2007 Aug;21(8):544-50.

PMID:
17711379
[PubMed - indexed for MEDLINE]
14.

Prevalence of antiretroviral drug resistance and resistance-associated mutations in antiretroviral therapy-naïve HIV-infected individuals from 40 United States cities.

Ross L, Lim ML, Liao Q, Wine B, Rodriguez AE, Weinberg W, Shaefer M.

HIV Clin Trials. 2007 Jan-Feb;8(1):1-8.

PMID:
17434843
[PubMed - indexed for MEDLINE]
Free Article
15.

Effects of drug resistance on viral load in patients failing antiretroviral therapy.

Machouf N, Thomas R, Nguyen VK, Trottier B, Boulassel MR, Wainberg MA, Routy JP.

J Med Virol. 2006 May;78(5):608-13.

PMID:
16555280
[PubMed - indexed for MEDLINE]
16.

Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy.

Balduin M, Sierra S, Däumer MP, Rockstroh JK, Oette M, Fätkenheuer G, Kupfer B, Beerenwinkel N, Hoffmann D, Selbig J, Pfister HJ, Kaiser R.

J Clin Virol. 2005 Dec;34(4):277-87. Epub 2005 Sep 26.

PMID:
16191482
[PubMed - indexed for MEDLINE]
17.

Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure.

Lohse N, Jørgensen LB, Kronborg G, Møller A, Kvinesdal B, Sørensen HT, Obel N, Gerstoft J; Danish HIV Cohort Study.

Antivir Ther. 2007;12(6):909-17.

PMID:
17926645
[PubMed - indexed for MEDLINE]
18.

Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.

Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, Matee MI, Gundersen SG, Bruun JN.

BMC Infect Dis. 2009 Jul 7;9:108. doi: 10.1186/1471-2334-9-108.

PMID:
19583845
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire.

Chaix ML, Rouet F, Kouakoussui KA, Laguide R, Fassinou P, Montcho C, Blanche S, Rouzioux C, Msellati P.

Pediatr Infect Dis J. 2005 Dec;24(12):1072-6.

PMID:
16371868
[PubMed - indexed for MEDLINE]
20.

Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viremia while receiving highly active antiretroviral therapy.

Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF.

Clin Infect Dis. 2004 Oct 1;39(7):1030-7. Epub 2004 Sep 1.

PMID:
15472857
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk